Join our 20.000 subscribers and receive the newsletter for free!

RELATED ARTICLES
Faeces transplant as treatment for Crohn's disease

Crohn’s disease is a complicated chronic disorder, the complexity of which has only become clear during the last decade. It has become increasingl…


GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Galapagos announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLO…


New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

Galapagos NV announced two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. …

POPULAR TAGS

New drug for intestinal fibrosis

Written by DS on in the category news with the tags , , , .


Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especially in patients with Crohn's disease. Today, intestinal fibrosis - the development of scar tissue in the intestines – can only be corrected with surgery. With a new drug, which first has to be tested extensively, this can possibly be avoided.

"The medicine we have tested decreases the formation of scar tissue and even partially shrinks existing fibrosis," says doctor Tom Holvoet, who is leading the research. "We found the cells that play an important role in the production of connective tissue. These cells are brought into a normal, resting state thanks to the new medicine. This means that they still perform their healing task in case of inflammation, but do not form any scar tissue."

The breakthrough is remarkable because relatively few researchers worldwide work on this problem. There also have not been a lot of successes yet. In the United States, another research group is working on a similar approach, but the researchers at the Ghent University Hospital already published the promising results in June in Gastroenterology.

Intestinal fibrosis occurs in the treatment of two chronic inflammatory bowel diseases (Crohn's disease, affecting 1 in 200 people and, to a lesser extent, ulcerative colitis). It is still unclear whether the drug, developed in collaboration with the Belgian company Amakem and taken over by the British company Redx Pharma, effectively will be marketed.

There are still extensive clinical studies that have to be done first, but the researchers are optimistic. "We already see that the drug is only locally active in the intestines and we expect few side effects. However, it may take several years until this drug will become available on the market," concludes Holvoet.

RELATED ARTICLES
Faeces transplant as treatment for Crohn's disease

Crohn’s disease is a complicated chronic disorder, the complexity of which has only become clear during the last decade. It has become increasingl…


GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Galapagos announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLO…


New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

Galapagos NV announced two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio Turnstone Biowin UGent NLO Janssen KU Leuven GSK V-Bio Ventures Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.